The efficacy of lasmiditan is used to alleviate migraine. We conduct a systematic review and meta-analysis to explore the influence of lasmiditan versus placebo on pain control in patients with migraine.
We search the PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through June 2020 for randomized controlled trials (RCTs) assessing the effect of lasmiditan versus placebo on pain control in patients with migraine. This meta-analysis was performed using the random effects model.
Four randomized controlled trials are included in the meta-analysis. Overall, compared with the control group, in patients with migraine, lasmiditan treatment shows positive impact on pain free at 2 hours [risk ratio (RR), 1.74; 95% confidence interval (CI), 1.47–2.07; P < 0.00001], headache response at 2 hours (RR, 1.38; 95% CI, 1.28–1.49; P < 0.00001), pain free at 24 hours (RR, 1.55; 95% CI, 1.16–2.07; P = 0.003), and no or mild disability level (RR, 1.20; 95% CI, 1.11–1.29; P < 0.00001), but has no obvious influence on nausea (RR, 2.22; 95% CI, 0.92–5.35; P = 0.08). In addition, lasmiditan seems to result in the increase in dizziness (RR, 6.36; 95% CI, 3.00–13.46; P < 0.0001) and paresthesia (RR, 5.10; 95% CI, 2.66–9.78; P < 0.00001).
Lasmiditan treatment provides additional benefits for pain control in patients with migraine.